Gsk (GLAXF) Other Working Capital Changes (2009 - 2022)
Gsk (GLAXF) recorded quarterly Other Working Capital Changes of -$900.4 million in Q1 2022, down 21.14% quarter-over-quarter from -$743.2 million in Q1 2021, and down 21.14% on a YoY basis from -$1.1 billion in Q1 2021.
Gsk (GLAXF) Other Working Capital Changes (2009 - 2022) Analysis & Trends
Gsk's Other Working Capital Changes history runs 6 years deep, the most recent figure standing at -$900.4 million for Q1 2022.
- In Q1 2022, Other Working Capital Changes fell 21.14% year-over-year to -$900.4 million; the TTM figure through Mar 2022 stood at -$1.6 billion (down 139.45% YoY), while the FY2020 annual figure was $154.1 million, down 77.27% from the prior year.
- Other Working Capital Changes was -$900.4 million for Q1 2022 at Gsk, down from -$743.2 million in the prior quarter.
- In the past five years, Other Working Capital Changes ranged from a high of -$743.2 million in Q1 2021 to a low of -$900.4 million in Q1 2022.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) |
|---|---|---|---|---|
| 1 | Gsk | 93,699,046.73 Bn | 93,699,041.77 Bn | 7.76 Bn |
| 2 | Eli Lilly | 1,012.06 Bn | 1,006.77 Bn | 16.22 Bn |
| 3 | Johnson & Johnson | 560.67 Bn | 538.62 Bn | 15.96 Bn |
| 4 | AbbVie | 402.20 Bn | 392.85 Bn | 10.78 Bn |
| 5 | Merck | 298.59 Bn | 292.94 Bn | 12.09 Bn |
| 6 | Amgen | 188.77 Bn | 176.74 Bn | 5.87 Bn |
| 7 | Gilead Sciences | 160.22 Bn | 152.49 Bn | 5.52 Bn |
| 8 | Pfizer | 148.19 Bn | 135.42 Bn | -1.21 Bn |
| 9 | Bristol Myers Squibb | 116.72 Bn | 106.26 Bn | 8.07 Bn |
| 10 | Gsk | - | - | 7.76 Bn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2022 | -900.37 Mn |
| Mar 31, 2022 | -900.37 Mn |
| Mar 31, 2021 | -743.24 Mn |
| Mar 31, 2021 | -743.24 Mn |
| Dec 31, 2013 | 30.76 Mn |
| Dec 31, 2013 | 30.76 Mn |
| Dec 31, 2012 | 12.85 Mn |
| Dec 31, 2012 | 12.85 Mn |
| Dec 31, 2011 | 31.43 Mn |
| Dec 31, 2011 | 31.43 Mn |
| Mar 31, 2009 | 31.61 Mn |
| Mar 31, 2009 | 31.61 Mn |